Public Health infection report
Volume 8 No 32 – 15th August 2014

Since 2009 there has been an increase in Fusidic Acid resistance growing from 11.7% in 2009 to 18.3% in 2013.



Reported resistance of MRSA bacteraemia isolates (voluntary reporting scheme): England, Wales & Northern Ireland 2009 - 2013

The Public Health England (PHE) cover Fusidic acid resistance in the staphylococcus health protection report which can be accessed here: **https://www.gov.uk/government/publications/staphylococcus-aureus-annual-trends-in-voluntary-surveillance**

PHE also have recently co-authored a paper on the subject available here: **http://www.sciencedirect.com/science/article/pii/S0924857915000643**

Try Terra-Cortril first-line for adults with localised infected eczema

Tried and trusted active ingredients – oxytetracycline hydrochloride and hydrocortisone

An alternative to cream treatments

Terra-Cortril does not contain preservatives

ABBREVIATED PRESCRIBING INFORMATION
TERRA-CORTRIL® Ointment
QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram of Terra-Cortril Ointment contains 30mg oxytetracycline as oxytetracycline hydrochloride Ph Eur and 10mg hydrocortisone Ph. Eur. **CLINICAL PARTICULARS Therapeutic indications** Terra-Cortril Ointment is indicated in the following disorders: exudative and secondarily infected eczema including atopic eczema, primary irritant dermatitis, allergic and seborrhoeic dermatitis. Secondarily infected insect bite reactions. In exudative flexural intertrigo Terra-Cortril Ointment can be used for up to seven days. Like other tetracyclines, oxytetracycline is generally ineffective against Pseudomonas and Proteus species. Because these are recognised secondary infecting organisms in exudative dermatoses, preliminary identification of the organism and determination of antibiotic sensitivity is important. **Posology and method of administration** After thorough cleansing of the affected skin areas, a small amount of the ointment should be applied gently. Applications should be made two to four times daily. Terra-Cortril Ointment is for topical administration only. *Use in the elderly:* No special precautions. *Use in children:* Not recommended. (See 'Contra-indications'). *Use in renal or hepatic impairment:* No special precautions. **Contra-indications** Hypersensitivity to one of the components of the preparation. Primary bacterial infections eg impetigo, pyoderma, furunculosis. *Pregnancy, lactation and in infants and small children:* because of the theoretical risk of damage to permanent dentition. **Special warnings and special precautions for use** Terra-Cortril Ointment should not be continued for more than seven days in the absence of any clinical improvement, since in this situation occult extension of infection may occur due to the masking effect of the steroid. Extended or recurrent application may increase the risk of contact sensitisation and should be avoided. The use of oxytetracycline and other antibiotics may result in an overgrowth of resistant organisms – particularly candida and staphylococci. Careful observation of the patient for this possibility is essential. If new infections due to nonsusceptible bacteria or fungi appear during therapy, Terra-Cortril should be discontinued. If extensive areas are treated, or if the occlusive technique is used, there may be increased systemic absorption of the corticosteroid and suitable precautions should be taken. If irritation develops, the product should be discontinued. Terra-Cortril Ointment is not recommended for ophthalmic use. **Undesirable effects** Hydrocortisone and oxytetracycline are well tolerated by the epithelial tissues and may be used topically with minimal untoward effects. Allergic reactions, including contact dermatitis may occur occasionally, but are rare. Reactions occurring most often from the presence of the anti-infective ingredients are allergic sensitisations. The following local side effects have been reported with topical corticosteroids, especially under occlusive dressings; burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria. The use of Terra-Cortril Ointment should be discontinued if such reactions occur. *Secondary infection:* The development of secondary bacterial or fungal infection has occurred after use of combinations containing steroids and antimicrobials. **MARKETING AUTHORISATION HOLDER** Alliance Pharmaceuticals Ltd, Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB. **MARKETING AUTHORISATION NUMBER** PL 16853/0096. **DATE OF FIRST AUTHORISATION** 27 December 1990. **DATE OF REVISION OF THE TEXT** 10/06/2011. **LEGAL CATEGORY** POM. Terra-Cortril is a registered trade mark. **Basic NHS price** £5.01 (excl. VAT) **Distributed by** Intrapharm Laboratories Limited, The Granary, The Courtyard Barns, Choke Lane, Cookham Dean, Maidenhead, Berkshire SL6 6PT. *For full prescribing information including details of interactions, pregnancy/lactation, driving/operating machinery and overdose see the Summary of Product Characteristics.* **Date of preparation** September 2012.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Redline Pharmacovigilance: Tel: 01908 363437; Fax: 0870 4321 279.

intrapharm laboratories

CCF-066-001
AL/1582/09.13/1.4
Date of preparation: September 2013